Doxocare 10 Injection is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Doxocare 10 Injection is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).

Doxocare 10 Injection contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.

Doxocare 10 Injection may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Doxocare 10 Injection. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Doxocare 10 Injection should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Doxocare 10 Injection is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Doxocare 10 Injection contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Doxocare 10 Injection is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma

Doxocare 10 Injection should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Doxocare 10 Injection is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Doxocare 10 Injection without a doctor’s advice, as it can cause serious health conditions. Doxocare 10 Injection is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.

• Avoid intercourse while on treatment with Doxocare 10 Injection.
• Regular complete blood count monitoring is advised.  Also, monitoring of liver function is important while receiving Doxocare 10 Injection.

• According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.